Home Cart Sign in  
Chemical Structure| 875787-07-8 Chemical Structure| 875787-07-8

Structure of LXR-623
CAS No.: 875787-07-8

Chemical Structure| 875787-07-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LXR-623 is a novel and brain-penetrant LXR agonist with IC50 values of 179 and 24 nM for LXRα and LXRβ, respectively.

Synonyms: WAY 252623

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LXR-623

CAS No. :875787-07-8
Formula : C21H12ClF5N2
M.W : 422.78
SMILES Code : FC(C1=CC=CC2=C(C3=CC=C(F)C=C3)N(CC4=CC=C(F)C=C4Cl)N=C12)(F)F
Synonyms :
WAY 252623
MDL No. :MFCD16495812
InChI Key :KYWWJENKIMRJBI-UHFFFAOYSA-N
Pubchem ID :16734800

Safety of LXR-623

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 cells 3 μM 24 hours LXR-623 induced ER stress and inhibited EMT, leading to increased expression of GRP78, CHOP, and E-cadherin, and decreased expression of vimentin. PMC8399758
HCT116 colon carcinoma cells 20 µM 24 hours LXR623 treatment resulted in reduced ATP levels, accompanied by energy deprivation and increased ATF4 protein levels. PMC6783693
U87 GBM cells 20 µM 24 hours LXR623 induced a dose-dependent increase in the cholesterol efflux transporter ABCA1, leading to depletion of cholesterol levels in GBM cells. PMC6783693
HUVECs 5 μM 24 hours Activated LXR, upregulated ABCA1 and ABCG1 expressions, reversed cholesterol accumulation caused by oxidative stress PMC10056126
Human foreskin fibroblasts (HFFs) 2.50 μM 24 hours LXR-623 inhibits CHIKV replication by upregulating the cholesterol exporter ABCA1, with an IC50 of 2.50 μM. PMC6709483
Human foreskin fibroblasts (HFFs) 10 μM 24 hours To test the effect of LXR-623 on CHIKV infection, showing that LXR-623 inhibits CHIKV replication by upregulating ABCA1. PMC6709483
Human foreskin fibroblasts (HFFs) 10 μM 24 hours To confirm the functionality of LXR-623 in HFFs, inducing the expression of known target genes ABCA1, RNF145, ApoE, and ABCG1. PMC6709483
Caco2 cells 1 μM 24 or 48 hours Evaluate FGF19 gene expression PMC2781308
MDA-MB-453 1, 2.5, 5 μM 24, 48, 72 h LXR-623 significantly inhibited the proliferation of MDA-MB-453 cells in a dose- and time-dependent manner. PMC6416354
BT549 1, 2.5, 5 μM 24, 48, 72 h LXR-623 significantly inhibited the proliferation of BT549 cells, induced apoptosis and S phase cell cycle arrest. PMC6416354
MDA-MB-231 1, 2.5, 5 μM 24, 48, 72 h LXR-623 significantly inhibited the proliferation of MDA-MB-231 cells, induced apoptosis and S phase cell cycle arrest. PMC6416354
MCF-7 1, 2.5, 5 μM 24, 48, 72 h LXR-623 significantly inhibited the proliferation of MCF-7 cells in a dose- and time-dependent manner. PMC6416354
Normal human astrocytes (NHA) 5 μM 48 hours To evaluate the effect of LXR-623 on normal astrocytes, results showed that NHAs were insensitive to LXR-623. PMC5479636
GBM39 cells 5 μM 48 hours To evaluate the effect of LXR-623 on GBM cells, results showed that LXR-623 significantly increased ABCA1 and IDOL expression and induced cell death. PMC5479636
U87EGFRvIII cells 5 μM 48 hours To evaluate the effect of LXR-623 on GBM cells, results showed that LXR-623 significantly increased ABCA1 and IDOL expression and induced cell death. PMC5479636
SK-N-SH cells 50 µM or 100 µM 48 hours To evaluate the effect of LXR-623 on flavivirus replication, results showed that LXR-623 significantly inhibited the replication of ZIKV and POWV. PMC8259867
ACHN cells 874.2 nM (IC50) 48 hours LXR623 significantly reduced intracellular cholesterol content and induced apoptosis by upregulating the cholesterol efflux gene ABCA1 and downregulating the cholesterol influx gene LDLR. PMC6538631
786-O cells 569.3 nM (IC50) 48 hours LXR623 significantly reduced intracellular cholesterol content and induced apoptosis by upregulating the cholesterol efflux gene ABCA1 and downregulating the cholesterol influx gene LDLR. PMC6538631
MDA-MB-231 cells 0, 1, 3, 5, 7, 9 µM 48 hours LXR-623 was found to slightly promote cell viability. PMC8399758
LN229 GBM cells 20 µM 72 hours LXR623 up-regulated the expression of the pro-apoptotic Bcl-2 family member Noxa, enhancing sensitivity to BH3 mimetics in an ATF4-dependent manner. PMC6783693
SF188 7.5, 15, 30 µM 72 hours Evaluate the therapeutic effect of LXR-623 in SF188 cells, determine IC50 value as 22.49 µM. PMC9405833
KNS42 7.5, 15, 30 µM 72 hours Evaluate the therapeutic effect of LXR-623 in KNS42 cells, determine IC50 value as 27.51 µM. PMC9405833
U373 7.5, 15, 30 µM 72 hours Evaluate the therapeutic effect of LXR-623 in U373 cells, determine IC50 value as 8.50 µM. PMC9405833
THP-1 macrophages 7 μM LXR-623 downregulated the expression of GRP78 and CHOP and reduced the lipid content of the cells. PMC7601278
Huh-7 cells 9 μM LXR-623 downregulated the expression of GRP78 and CHOP and reduced the lipid and cholesterol content of the cells. PMC7601278

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCT116 colon carcinoma xenograft model Intraperitoneal 100-200 mg/kg 3 days per week for 1.5 weeks Combination treatment of LXR623 and ABT263 significantly inhibited tumor growth more effectively than single treatments. PMC6783693
Cynomolgus monkeys Normal lipid levels Oral 15 and 50 mg/kg/day Once daily for 28 days Significantly reduced total and LDL cholesterol, increased expression of target genes ABCA1/G1 in peripheral blood cells PMC2781308
Nude mice Intracranial GBM xenograft model Oral gavage 400 mg/kg Daily, starting at day seven post-injection To evaluate the anti-tumor effect of LXR-623 in vivo, results showed that LXR-623 significantly inhibited tumor growth and prolonged survival. PMC5479636
Female nude mice MDA-MB-231 xenograft model Oral 50 mg/kg Once daily for 10 days LXR-623 significantly inhibited tumor growth, reducing tumor volume and weight. PMC6416354
Nude mice 786-O cell xenograft model Intraperitoneal injection 60 mg/kg Once daily for 42 days SR9243 significantly inhibited the growth of 786-O cell xenografts, reduced tumor volume and weight, and had no significant effect on the body weight of nude mice. PMC6538631

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00385489 Healthy PHASE1 COMPLETED 2025-09-06 Toshima-ku, Tokyo, 171-0014, J... More >>apan Less <<
NCT00366522 Healthy PHASE1 COMPLETED 2025-09-06 Lincoln, Nebraska, 68502, Unit... More >>ed States Less <<
NCT00379860 Healthy Subjects PHASE1 TERMINATED 2025-01-07 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.83mL

2.37mL

1.18mL

23.65mL

4.73mL

2.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories